Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest CF Stories

2014-02-18 04:20:49

ALBANY, New York, February 18, 2014 /PRNewswire/ -- MarketResearchReports.Biz includes new market research report " Cystic Fibrosis Therapeutics In Major Developed Markets To 2019 - CFTR Modulators Initiate Drive Towards Personalized Treatment And Market Growth" to its large collection of research reports....

2014-02-06 23:25:01

ResearchMoz.us include new market research report "Cystic Fibrosis Therapeutics in Major Developed Markets to 2019" to its huge collection of research reports. Full Report @ http://www.researchmoz.us/cystic-fibrosis-therapeutics-in-major-developed-markets-to-2019-cftr-modulators-initiate-drive-towards-personalized-treatment-and-market-growth-report.html Albany, NewYork (PRWEB) February 06, 2014 GBI Research has released its pharma report “Cystic Fibrosis Therapeutics in Major...

2014-01-21 23:00:28

Cactus Technologies, Ltd. today announced the launch of the new 220 Series Commercial Grade Compact Flash product. This product meets the industry standard CF type I form factor as defined by the Compact Flash Association and is offered in capacities from 4GB through 128GB. Winter Springs, FL (PRWEB) January 21, 2014 Cactus Technologies, Ltd. today announced the launch of the new 220 Series Commercial Grade Compact Flash product. This product meets the industry standard CF type I form...

2013-07-11 12:29:39

Virtium is steadfast in its commitment to the industrial embedded market and plans to support CompactFlash well into the next decade RANCHO SANTA MARGARITA, Calif., July 11, 2013 /PRNewswire/ -- Virtium, a leading provider of storage and memory solutions for industrial embedded systems, today announced its next-generation TuffDrive(TM) CompactFlash (CF) cards, which offer the industry's highest capacity at 64 gigabytes (GB) based on SLC NAND flash. Designed to deliver the latest...

2013-05-17 16:24:14

Cystic Fibrosis Foundation Announces "Walk Weekend" - Great Strides Fundraising Events Held Nationwide May 18-19 BETHESDA, Md., May 17, 2013 /PRNewswire-USNewswire/ -- Walks in nearly every state this weekend will raise funds to fight cystic fibrosis as part of Great Strides, the Cystic Fibrosis Foundation's largest national fundraising event. Cystic fibrosis is a fatal genetic disease that causes debilitating lung infections and premature death. "Every walker who joins Great...

2013-05-01 12:28:03

- Forty students will receive $2,500 scholarships for the 2013-2014 school year NORTH CHICAGO, Ill., May 1, 2013 /PRNewswire/ -- AbbVie today announced that undergraduate and graduate students living with cystic fibrosis (CF) can now apply for the AbbVie CF Scholarship for the 2013-2014 academic school year. Previously known as the CFCareForward Scholarship, the AbbVie CF Scholarship was established 21 years ago to honor young adults with CF as they pursue goals of higher...

2011-09-01 08:10:00

VANCOUVER, British Columbia, Sept. 1, 2011 /PRNewswire-Asia/ -- Insiderslab.com has issued insider trading reports and Equity Research for the following companies today: Rackspace Hosting (NYSE:RAX), Nu Skin (NYSE:NUS), Biogen Idec (NASDAQ:BIIB), priceline.com (NASDAQ:PCLN), CF (NYSE:CF) & C.H. Robinson Worldwide (NASDAQ:CHRW). (Logo: http://photos.prnewswire.com/prnh/20100419/HKM001LOGO ) Hot penny stocks and good investment opportunities can often be discovered by following insider...

2011-08-17 08:10:00

VANCOUVER, British Columbia, Aug. 17, 2011 /PRNewswire-Asia/ -- Insiderslab.com has issued insider trading reports and Equity Research for the following companies today: Ciena (NASDAQ:CIEN), Rackspace (NYSE:RAX), Acme Packet (NASDAQ:APKT), Accenture (NYSE:ACN), Sara Lee (NYSE:SLE) & CF (NYSE:CF). (Logo: http://photos.prnewswire.com/prnh/20100419/HKM001LOGO ) These trades are significant because these insiders have 'hands-on' roles (CEOs, CFOs, and COOs) within their respective...

2011-07-01 07:00:00

SOUTH PLAINFIELD, N.J., July 1, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the publication of data from a Phase 2 study of ataluren, an investigational new drug, in adults with nonsense mutation cystic fibrosis (nmCF) in the European Respiratory Journal. The published three-month data showed that treatment with ataluren resulted in statistically significant improvements in chloride channel activity, CF-related cough and positive trends in lung function. (Logo:...

2010-12-21 07:00:00

SOUTH PLAINFIELD, N.J., Dec. 21, 2010 /PRNewswire/ -- PTC Therapeutics, Inc. announced today that it has completed enrollment of a Phase 3 clinical trial of ataluren, an investigational new drug, in patients with nonsense mutation cystic fibrosis (nmCF). (Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) The 48-week study is designed to determine whether ataluren can improve lung function in patients with nmCF. The trial has enrolled 238 patients at 36 sites in North America,...